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CeBACKGROUND Angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), beta-blockers
and statins are recommended after acute myocardial infarction (AMI). Patients may adhere to some, but not all, therapies.
OBJECTIVES The authors investigated the effect of tradeoffs in adherence to ACE inhibitors/ARBs, beta-blockers, and
statins on survival among older people after AMI.
METHODS The authors identified 90,869 Medicare beneficiaries $65 years of age who had prescriptions for ACE
inhibitors/ARBs, beta-blockers, and statins, and survived $180 days after AMI hospitalization in 2008 to 2010.
Adherence was measured by proportion of days covered (PDC) during 180 days following hospital discharge. Mortality
follow-up extended up to 18 months after this period. The authors used Cox proportional hazards models to estimate
hazard ratios of mortality for groups adherent to 2, 1, or none of the therapies versus group adherent to all
3 therapies.
RESULTS Only 49% of the patients adhered (PDC $80%) to all 3 therapies. Compared with being adherent to all 3
therapies, multivariable-adjusted hazard ratios (95% confidence intervals [CIs]) for mortality were 1.12 (95% CI: 1.04 to
1.21) for being adherent to ACE inhibitors/ARBs and beta-blockers only, 0.98 (95% CI: 0.91 to 1.07) for ACEI/ARBs and
statins only, 1.17 (95% CI: 1.10 to 1.25) beta-blockers and statins only, 1.19 (95% CI: 1.07 to 1.32) for ACE inhibitors/ARBs
only, 1.32 (95% CI: 1.21 to 1.44) for beta-blockers only, 1.26 (95% CI: 1.15 to 1.38) statins only, and 1.65 (95% CI: 1.54 to
1.76) for being nonadherent (PDC <80%) to all 3 therapies.
CONCLUSIONS Patients adherent to ACE inhibitors/ARBs and statins only had similar mortality rates as those
adherent to all 3 therapies, suggesting limited additional benefit for beta-blockers in patients who were adherent
to statins and ACE inhibitors/ARBs. Nonadherence to ACE inhibitors/ARBs and/or statins was associated with
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1544C linical guidelines recommendprescribing angiotensin-convertingenzyme (ACE) inhibitors/angiotensin
II receptor blockers (ARB), beta-blockers,
and statins after an acute myocardial infarc-
tion (AMI). The effectiveness of these
guideline-recommended preventive therapies
is dependent on patient adherence (1–4).
However, a recent U.S. study reported that
almost 40% of the patients who initiated use
of ACE inhibitors/ARBs, beta-blockers or sta-
tins following hospitalization for AMI became
nonadherent during the first treatment year
(5). Many seem to do so already during thefirst 6 months (6). Studies from other countries also
suggest sub-optimal adherence to preventive thera-
pies for the secondary prevention of cardiovascular
disease (CVD) (7–9).SEE PAGE 1555Adhering to multiple therapies can present
considerable challenges for older adults with multiple
comorbidities and medications. The proportion of
adults 65 years of age and older who take 5 or more
prescription medications tripled from 13% to 39%
between 1988 and 2010 (10). Patients with multiple
comorbidities and polypharmacy have an increased
risk of drug–drug interactions and adverse drug
events (11). Furthermore, therapeutic and medication
regimen complexity may decrease medication
adherence (12,13). Patients may have tradeoffs in
adherence; in other words, they may choose to
adhere to some post-AMI preventive therapies, but
not to others. Studies have shown notable variation in
adherence across post-AMI preventive therapies
(1,5,9,14,15). Clinicians who manage patients with
complex treatment regimens are required to balance
benefits and risks of preventive therapies, because
evidence from randomized clinical trials mostly re-
lates to the efficacy of a single preventive therapy on
survival following AMI rather than combinations of
therapies (16,17). Indeed, post-AMI beta-blocker trials
were largely performed before statin use became
widespread, and additive efficacy of beta-blockers in
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received April 21, 2017; revised manuscript received July 20, 201If a patient is not able to adhere to all post-AMI
preventive therapies long term, which therapies
should clinicians emphasize for patient adherence?
Little is known about the clinical impact of the
tradeoffs in adherence made among the preventive
therapies after AMI. Thus, the objective of this study
was to investigate the effects of tradeoffs in adher-
ence to ACE inhibitors/ARBs, beta-blockers, and sta-
tins on all-cause mortality after AMI in a large cohort
of Medicare beneficiaries.
METHODS
DATA SOURCES AND STUDY COHORT. Data were
sourced from the Center for Medicare & Medicaid
Services Medicare Chronic Condition Data Warehouse
2007 to 2011 files that include enrollment summaries
and inpatient, outpatient, skilled-nursing facility,
physician office visits, and prescription claims. We
first identified all Medicare beneficiaries meeting the
following eligibility criteria: 1) age 65 years or older;
2) continuous enrollment for $365 days before
and $180 days after the index AMI hospitalization in
the Medicare fee-for-service and Part D prescription
benefits; 3) index AMI hospitalization between
January 1, 2008, and December 31, 2010; 4) discharge
to home, and 5) survival for >180 days after the index
hospitalization (Figure 1). Patients hospitalized for
AMI were identified using an International Classifi-
cation of Diseases, Ninth Revision, code of 410.x1
recorded either in the primary or secondary discharge
diagnosis field in the inpatient files (5). The index
AMI hospitalization was defined as each patient’s first
hospitalization for AMI between 2008 and 2010. The
final study population comprised patients who had all
3 preventive therapies (ACE inhibitors/ARBs, beta-
blockers, and statins) within 30 days of the index
hospital discharge (Figure 1). Having a preventive
therapy was defined as either having filled a pre-
scription during the 30-day period, or having enough
medication supply from a prescription filled before
the AMI hospitalization to cover the 30-day period
after discharge.
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FIGURE 1 Flowchart of the Study Population
Medicare beneficiaries who had AMI in 2008 and were continuously
enrolled in Medicare parts A/B/D in 2007 and 2008, N = 160,067
Medicare beneficiaries who had AMI in 2009 and were continuously
enrolled in Medicare parts A/B/D in 2008 and 2009, N = 148,639
Medicare beneficiaries who had AMI in 2010 and were continuously
enrolled in Medicare parts A/B/D in 2009 and 2010, N = 155,151
N = 463,857
Excluded:
Patients admitted for index AMI prior to January 1st of the base year (n = 9,810)
Patients age < 65 at the beginning of the baseline period (n = 64,691)
Patients living outside of the U.S., having unknown ZIP code (n = 960)
Patients with missing discharge date (n = 120)
Patients with less than 12-month enrollment in Medicare Parts A/B/D prior to index AMI (n = 2,346)
Patients who died during hospital admission (n = 54,216)
Patients who had discharge code to hospice (n = 15,525)
Patients who had discharge code to skilled nursing facility (n = 111,336)
Patients with end stage renal disease at baseline (n = 22,381)
Patients who died within 180 days after discharge (n = 138,038)
Patients who dis-enrolled from Medicare Part D within 180 days after discharge (n = 1,088)
Excluded:
Patients who did not fill prescriptions for all three study medications within 30 days after discharge:
- no fill for ACEI/ARB (n = 63,715)
- no fill for beta-blockers (n = 52,584)
- no fill for statins (n = 32,262)
N = 192,746
Final cohort, N = 90,869
ACEI/ARB ¼ angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; AMI ¼ acute myocardial infarction.
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1545characteristics, adherence and outcomes is shown in
Online Figure 1. We measured adherence for 180 days
following hospital discharge. We calculated the pro-
portion of days covered (PDC) over the entire
180 days using Medicare Part D prescription claims
files to measure patient adherence to a therapy (5).
The PDC was calculated using dates and days of
supply of the prescriptions filled. We classified pa-
tients as adherent (PDC $80%) or nonadherent
(<80%) separately to each of the 3 preventive thera-
pies. Previous research has shown that post-AMI pa-
tients benefit from use of preventive therapies at the
adherence levels of $80% (2). Tradeoffs in medica-
tion adherence were assessed by adherence cate-
gories to the 3 therapies. We had the following 8
categories: 1) adherent to all 3 therapies; 2) adherent
to ACE inhibitors/ARBs and beta-blockers only; 3)
adherent to ACE inhibitors/ARBs and statins only;
4) adherent to beta-blockers and statins only; 5)
adherent to ACE inhibitors/ARBs only; 6) adherent tobeta-blockers only; 7) adherent to statins only; and 8)
adherent to none of the 3 therapies.
ASSESSMENT OF OUTCOME. Mortality was measured
using the verified date of death from the Medicare
enrollment file. Patients were followed-up for death
from the end of the 180-day adherence assessment
period up to 18 months (Online Figure 1).
PATIENT CHARACTERISTICS. All covariates were
measured prior to the adherence assessment period
(Online Figure 1). Clinical characteristics included the
Charlson Comorbidity Index, diagnoses of any CVD
and other risk factors for mortality in the 365-day
baseline period before index AMI hospitalization.
The baseline CVD diagnoses and risk factors
included AMI, coronary artery bypass graft surgery,
percutaneous coronary intervention, stroke/transient
ischemic attack, unstable angina, angina pectoris,
ischemic heart disease, heart failure, atrial fibrilla-
tion, peripheral vascular disease, hypertension,
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1546diabetes mellitus, hyperlipidemia, cancer, depression
and dementia/Alzheimer’s disease, and baseline po-
tential intolerant conditions/contraindications to the
preventive therapies including chronic kidney dis-
ease, liver disease, chronic obstructive pulmonary
disease, and asthma. In addition, dispensations of
ACE inhibitors/ARBs, beta-blockers, and statins
within the 180 days before the index AMI hospitali-
zation were included as were AMI type (ST-segment
elevation versus non–ST-segment elevation myocar-
dial infarction), revascularization procedures (angi-
ography, coronary artery bypass graft surgery,
percutaneous coronary intervention, cardiac cathe-
terization, infusion of thrombolytic and/or platelet
inhibitors), complications (heart failure, cardiogenic
shock, acute renal failure, hypotension, cardiac
dysrhythmias), total intensive care unit and inpatient
days measured during the index hospitalization, and
sociodemographic variables (sex, age, median
household income of U.S. Census block groups, state
of residence, and insurance status) measured before
the index AMI hospitalization.
We included an additional set of covariates to
reduce potential confounding bias by frailty. Frailty is
a strong risk factor for mortality in older people
(18,19) and may affect adherence. This additional set
included the following variables previously found to
predict dependency in activities of daily living in
Medicare population: use of ambulance transport,
wheelchair, podiatric care, rehabilitation services,
and screening tests, treatment for coagulation defi-
ciency and lipid abnormality, as well as diagnoses for
decubitus ulcer, falls/difficulty walking, obesity,
bladder dysfunction, infection/sepsis, neurological
disorder, osteoarthritis, paralysis, Parkinson disease,
pulmonary circulation disorder, vertigo, weakness,
and weight loss (19).
STATISTICAL ANALYSES. The distributions of pa-
tient characteristics, adherence, and outcome events
were assessed by the categories of adherence to the
therapies. Categorical variables were expressed as
numbers and percentages, and continuous variables
as mean  SD. Kaplan-Meier estimators were applied
to estimate the crude mortality rate at 1-year follow-
up. We used Cox proportional hazards models to es-
timate hazard ratios (HRs) and their 95% confidence
intervals (CIs) for all-cause mortality associated with
other adherence groups in comparison with the group
adherent to all 3 therapies. The model adjusted for all
patient characteristics measured. The adjusted sur-
vival curves of the adherence groups were also
plotted (20). The adjusted mortality rates at 1-year
follow-up were estimated from the model. Weassessed the proportional hazards assumption using 2
methods: Schoenfeld residuals test (Online Table 1)
and graphical examination for crossover of Kaplan-
Meier curves (Central Illustration). The Schoenfeld
residuals test only showed very weak correlation be-
tween the Schoenfeld residuals for the groups
adherent to ACE inhibitors/ARBs only and adherent
to none of the therapies and time, and there was no
crossover between their curves and the curve of the
reference group (adherent to all 3 therapies). The
assessment suggests that although the HRs may not
be constant over time for the 2 adherence groups,
inference on their HRs as average effects over time
will still be valid.
Given the compelling indication of ACE inhibitors/
ARBs for managing heart failure and diabetes, and
polypharmacy burden for cognitively impaired pa-
tients, we additionally conducted subgroup analyses
stratified by heart failure (either pre-admission or
during admission), diabetes, and dementia, as well as
age group (65 to 74 years, 75 to 84 years, 85þ years)
and sex. We tested for statistical significance of the
heterogeneity of the association between adherence
group and mortality across the subgroups defined by
presence of heart failure by including a product term
“heart failure*adherence group” in the model, and
similarly for presence of diabetes and dementia, and
finally for age group and sex.
In the sensitivity analysis, we additionally
adjusted for polypharmacy (total number of unique
medication classes with prescriptions filled in the
30 days after hospital discharge) and average daily
dose of the last prescription for each of the 3 therapies
filled in the 30 days after hospital discharge from Part
D prescription files. All statistical analyses were per-
formed with SAS version 9.4 (SAS Institute, Cary,
North Carolina).
RESULTS
STUDY COHORT AND ADHERENCE GROUPS. Overall,
466,385 beneficiaries suffered an index AMI during
the study period. Among these beneficiaries 192,746
patients met all the eligibility criteria. Of these pa-
tients 63,715 (33.1%) did not fill any prescriptions for
ACE inhibitors/ARBs; 52,584 (27.3%) filled no pre-
scriptions for beta-blockers, and 32,262 (16.7%) filled
no prescriptions for statins within 30 days after the
index discharge. The final study populations con-
sisted of 90,869 patients who had all 3 therapies
within the 30 days.
More than one-half of the patients (51.5%) were
nonadherent to 1 or more of the 3 preventive thera-
pies during the 180-day adherence assessment
CENTRAL ILLUSTRATION Adherence Tradeoff to Preventive Therapies and Survival
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Adjusted survival curves of all-cause mortality by adherence categories to preventive therapies. Adjusted for patient characteristics shown in Online Table 2 and total
intensive care unit and inpatient days. ACEI/ARB ¼ angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers.
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1547period. Overall, 27,911 patients (30.7%) were non-
adherent to ACE inhibitors/ARBs, 21,589 (23.8%) were
nonadherent to beta-blockers, and 20,861 (23.0%)
were nonadherent to statins. Table 1 shows selected
baseline characteristics of the final study population
according to the adherence category (see Online
Table 2 for the distributions of all covariates).
MORTALITY IN THE WHOLE COHORT. Of the final
study population, 9,617 (10.6%) died during the mean
follow-up of 347 days. Crude and adjusted mortality
rates among patients who were adherent to all 3
therapies were 8.9% and 9.3% at 1-year follow-up,
respectively (Figure 2). The 1-year crude and
adjusted mortality rates for patients who were non-
adherent to all 3 therapies were 16.1% and 14.3%,
respectively. Figure 2 shows that those who were
adherent to ACE inhibitors/ARBs and statins only hadsimilar mortality as those adhering to all 3 therapies
(adjusted HR: 0.98; 95% CI: 0.91 to 1.07). Those who
were nonadherent to all 3 therapies had highest
mortality (HR: 1.65; 95% CI: 1.54 to 1.76), followed by
those who were adherent to beta-blockers only (HR:
1.32; 95% CI: 1.21 to 1.44), to statins only (HR: 1.26;
95% CI: 1.15 to 1.38), to ACE inhibitors/ARBs only (HR:
1.19; 95% CI: 1.07 to 1.32), to beta-blockers and statins
only (HR: 1.17; 95% CI: 1.10 to 1.25), and to ACE
inhibitors/ARBs and beta-blockers only (HR: 1.12; 95%
CI: 1.04 to 1.21). The adjusted survival curves are
presented in the Central Illustration. Adjustment for
additional variables suggestive of pre-admission
frailty did not appreciably change the HRs already
adjusted for conventional sociodemographic and
clinical variables (Online Table 3). The sensitivity
analysis by additionally adjusting for polypharmacy
TABLE 1 Selected Baseline Characteristics of the Study Population Stratified by Adherence to the 3 Classes of Preventive Therapies
Cohort
(N ¼ 90,869)
(100%)
Adherent To
All 3
Therapies
(n ¼ 44,051)
(48.5%)
ACE Inhibitor/
ARB þ Beta-Blocker
Only
(n ¼ 8,269) (9.1%)
ACE Inhibitor/
ARB þ Statin
Only
(n ¼ 7,242) (8.0%)
Beta-Blocker þ
Statin Only
(n ¼ 12,401)
(13.6%)
ACE Inhibitor/
ARB Only
(n ¼ 3,396)
(3.7%)
Beta-Blocker
Only
(n ¼ 4,559)
(5.0%)
Statin Only
(n ¼ 4,304)
(4.7%)
None
(n ¼ 6,647)
(7.3%)
Sociodemographics
Age, yrs
65–74 43.6 44.6 43.3 43.1 41.2 43.1 41.8 43.5 43.7
75–84 39.7 39.2 40.1 43.7 41.3 39.7 40.3 40.4 38.4
85þ 16.7 16.1 17.6 17.2 17.6 17.2 17.9 16.2 17.9
Sex, male 45.2 45.4 40.9 45.5 45.9 41.4 43.0 51.5 47.3
Race
White 85.0 86.1 84.5 84.8 87.1 80.0 85.1 86.2 76.6
Black 8.0 7.1 8.7 7.9 6.6 11.4 8.7 7.0 14.0
Hispanic 2.9 2.7 3.2 3.2 2.4 4.3 2.9 2.5 4.4
Asian 2.2 2.2 1.7 2.1 2.3 2.4 1.5 2.4 2.4
Other 1.9 1.9 1.9 2.0 1.6 1.9 1.8 1.9 2.7
Income proxy*
#$30,000 47.2 46.9 47.7 46.4 45.6 51.4 46.0 44.5 52.1
$30,001–$60,000 41.4 41.7 41.2 42.3 42.4 37.9 42.1 42.5 37.5
$60,001–$100,000 9.2 9.2 9.1 9.1 9.7 8.3 9.9 10.4 8.3
$100,001–$150,000 1.7 1.7 1.6 1.7 1.6 1.9 1.5 2.0 1.7
$$150,001 0.5 0.5 0.4 0.6 0.6 0.5 0.4 0.7 0.4
Having Part D
prescription drug
benefit gap
(“doughnut hole”)
12.7 13.5 12.0 13.1 13.4 11.6 11.3 12.0 9.3
Medicare & Medicaid dual
eligibility
23.5 24.4 21.5 22.6 21.2 25.7 19.8 19.3 29.6
Clinical characteristics (within 12 months before index admission)
AMI 2.8 2.7 3.0 2.6 2.8 2.5 3.6 3.0 3.1
CABG 0.7 0.7 0.6 0.8 0.9 0.6 0.8 0.9 0.6
PCI 4.8 4.8 4.8 4.8 4.7 4.7 5.7 4.6 4.6
Stroke/TIA 6.0 5.6 5.9 6.4 6.1 6.2 7.3 6.5 7.2
Unstable angina 3.8 3.7 3.8 3.9 4.2 4.5 4.2 3.5 3.5
Angina pectoris 6.2 6.2 6.1 6.5 6.5 6.3 7.2 5.9 5.4
IHD 44.0 43.0 45.2 44.8 45.4 43.5 47.9 43.8 43.0
CHF 20.7 19.8 21.7 19.6 22.5 21.4 22.8 19.5 22.8
Atrial fibrillation 9.7 9.3 10.4 9.9 10.9 9.3 10.9 9.9 8.1
Hypertension 75.6 75.2 78.2 76.7 76.6 77.9 78.7 71.4 71.1
PVD 17.3 16.6 17.6 17.3 18.6 16.8 19.5 17.3 17.8
Hyperlipidemia 59.3 59.5 60.0 60.2 61.5 56.4 60.7 60.5 51.2
Diabetes 40.0 40.0 40.7 39.8 40.3 41.0 42.0 38.0 38.3
CKD 11.4 10.2 10.5 10.4 15.1 10.6 14.8 12.5 11.9
COPD 21.3 19.8 21.7 21.8 22.5 23.5 21.2 23.9 24.7
Asthma 5.1 4.6 5.2 5.4 5.5 6.4 5.0 5.7 6.2
Liver disease 1.5 1.5 1.8 1.1 1.4 1.9 1.6 1.5 1.8
Cancer 10.4 9.9 10.8 10.4 11.2 9.8 12.1 11.6 9.76
Depression 13.0 12.1 13.1 13.3 13.7 14.2 14.6 14.5 15.3
Dementia/Alzheimer
disease
9.5 7.2 7.0 8.4 7.4 9.8 8.7 8.7 11.8
Charlson Comorbidity Index
0 30.7 32.2 29.7 30.4 28.8 29.0 27.0 30.4 30.0
1–2 39.8 40.1 40.3 40.8 38.5 41.4 39.2 39.0 39.1
3–5 23.4 22.2 24.3 23.3 25.3 24.1 25.5 23.9 24.3
6–8 5.0 4.6 4.7 4.5 6.3 4.4 6.7 5.4 5.4
9þ 1.1 0.9 1.0 1.0 1.2 1.2 1.6 1.4 1.2
Continued on the next page
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TABLE 1 Continued
Cohort
(N ¼ 90,869)
(100%)
Adherent To
All 3
Therapies
(n ¼ 44,051)
(48.5%)
ACE Inhibitor/
ARB þ Beta-Blocker
Only
(n ¼ 8,269) (9.1%)
ACE Inhibitor/
ARB þ Statin
Only
(n ¼ 7,242) (8.0%)
Beta-Blocker þ
Statin Only
(n ¼ 12,401)
(13.6%)
ACE Inhibitor/
ARB Only
(n ¼ 3,396)
(3.7%)
Beta-Blocker
Only
(n ¼ 4,559)
(5.0%)
Statin Only
(n ¼ 4,304)
(4.7%)
None
(n ¼ 6,647)
(7.3%)
Pre-admission medication use (within 180 days before index admission)
ACE inhibitor/ARB 69.5 70.8 73.5 73.0 69.1 73.9 66.7 60.5 58.9
Beta-blocker 56.6 58.8 61.6 51.1 58.2 48.3 62.9 48.6 44.3
Statin 61.2 63.7 55.5 67.0 64.5 52.0 54.3 63.9 47.7
Characteristics of index admission
NSTEMI 71.9 70.7 72.7 73.8 72.4 74.3 73.8 71.4 73.7
CHF 35.3 34.7 35.1 31.8 38.4 34.5 37.6 35.0 37.0
Cardiogenic shock 2.7 2.7 2.4 2.0 3.6 2.2 2.8 3.4 2.3
Cardiac arrest 1.2 1.2 1.1 0.9 1.2 0.8 1.5 1.6 0.9
Acute renal failure 12.2 10.3 11.0 10.7 18.0 10.4 15.5 14.6 13.3
Cardiac dysrhythmias 30.2 29.9 31.6 31.0 31.2 29.3 31.0 30.7 27.3
Hypotension 5.0 4.8 4.5 5.1 5.6 4.7 5.0 6.1 4.6
Angiocardiography 67.4 69.1 66.3 67.5 66.3 65.6 64.2 67.9 62.0
CABG 7.7 7.0 6.7 7.2 11.0 6.5 8.6 10.0 6.4
PCI 48.6 51.6 47.0 48.4 46.0 46.4 42.9 46.8 41.6
Cardiac catheterization 67.7 69.3 66.7 67.9 66.7 66.3 65.2 67.7 62.5
Thrombolytic use for AMI 0.7 0.7 0.8 0.6 0.5 0.8 0.6 0.7 0.7
Antiplatelet use for AMI 5.4 5.6 5.3 5.6 5.4 4.8 4.9 5.3 4.9
Adherence (PDC), mean (during 180 days after the index discharge)
ACE inhibitor/ARB 0.81 0.97 0.96 0.96 0.45 0.94 0.46 0.46 0.45
Beta-blocker 0.86 0.97 0.96 0.53 0.97 0.53 0.95 0.52 0.48
Statin 0.85 0.97 0.52 0.95 0.96 0.51 0.51 0.94 0.46
Follow-up days, mean 347 351 347 352 344 345 344 347 335
Values are % unless otherwise stated. *Average household income at Census block groups of residence among residents who were age 65 years and older.
ACE inhibitor/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; AMI ¼ acute myocardial infarction; CABG ¼ coronary artery bypass surgery; CHF ¼ congestive heart failure;
CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; IHD ¼ ischemic heart disease; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary
interventions; PDC ¼ proportion of days covered; PVD ¼ peripheral vascular disease; TIA ¼ transient ischemic attack.
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1549and dose of the 3 therapies yielded very similar and
consistent findings (Online Table 4).
MORTALITY IN PATIENT SUBGROUPS. We observed
some variation in the associations across subgroups
of patients with and without heart failure, diabetes,
and dementia (p values for interactions heart
failure*adherence group 0.176, diabetes*adherence
group 0.002, and dementia*adherence group 0.032).
The results of subgroup analyses comparing other
adherence groups to the group adherent to all 3
therapies are presented in Figure 3. Overall, di-
rections of all associations between adherence groups
and mortality in patients with heart failure and dia-
betes were similar to those in the whole study pop-
ulation, with patients who were nonadherent to all 3
therapies having the highest mortality. Mortality in
patients who were adherent to ACE inhibitors/ARBs
and statins only was not significantly different to
mortality in those who were adherent to all 3 thera-
pies in any of the subgroups. Nonetheless, the HR of
mortality for patients who were adherent to ACEinhibitors/ARBs only versus all 3 therapies was 1.38
(95% CI: 1.16 to 1.65) among patients without heart
failure and 1.10 (95% CI: 0.96 to 1.26) with heart
failure. The HR of mortality for patients who were
adherent to ACE inhibitors/ARB only versus all 3
therapies was 1.14 (95% CI: 0.97 to 1.33) among pa-
tients without diabetes and 1.24 (95% CI: 1.07 to 1.43)
with diabetes. The HR of mortality for patients who
were adherent to beta-blockers only versus all 3
therapies was 1.18 (95% CI: 1.04 to 1.34) among pa-
tients without diabetes and 1.44 (95% CI: 1.28 to 1.62)
with diabetes. The HR of mortality for patients who
were adherent to statins only versus all 3 therapies
was 1.38 (95% CI: 1.07 to 1.43) among patients without
diabetes and 1.12 (95% CI: 0.98 to 1.29) with diabetes.
Compared were patients without dementia, patients
with dementia had higher mortality when adherent to
ACE inhibitors/ARB and beta-blockers only (HR: 1.09;
95% CI: 1.01 to 1.18; and HR: 1.29; 95% CI: 1.06 to 1.55)
and to beta-blockers only (HR: 1.29; 95% CI: 1.17 to
1.42; and HR: 1.58; 95% CI: 1.28 to 1.95) versus 3
therapies. The effects of adherence tradeoffs on
FIGURE 2 Crude and Adjusted Rates and HRs (95% CIs) of All-Cause Mortality by Adherence Categories to Preventive Therapies in the Whole Study Cohort
ACEI/ARB + Beta-Blocker + Statin
Beta-Blocker + Statin Only
Statin Only
None
Beta-Blocker Only
ACEI/ARB + Statin Only
ACEI/ARB Only
ACEI/ARB + Beta-Blocker Only
Ref
1.17 (1.1-1.25)
1.26 (1.15-1.38)
1.65 (1.54-1.76)
1.32 (1.21-1.44)
0.98 (0.91-1.07)
1.19 (1.07-1.32)
1.12 (1.04-1.21)
Adherence Group
3,995 (9.1%)
1,448 (11.7%)
530 (12.3%)
1,091 (16.4%)
618 (13.6%)
670 (9.3%)
381 (11.2%)
884 (10.7%)
Total No. of
Mortality
(Event Rate)
8.9%
11.6%
12.1%
16.1%
12.8%
8.9%
11.1%
10.5%
Crude K-M
Mortality Rate
at 1 Year
Ref
1.31 (1.23-1.40)
1.37 (1.25-1.50)
1.89 (1.77-2.02)
1.52 (1.40-1.66)
1.02 (0.94-1.10)
1.26 (1.13-1.40)
1.19 (1.11-1.28)
Crude HR for
Mortality
(95% CI)
Adjusted HR for Mortality (95% CI)
9.3%
Adjusted
Mortality Rate
at 1 Year
10.9%
11.5%
14.3%
11.6%
9.1%
10.9%
10.3%
0.5 0.75 1 1.25 1.5 1.75 2
Reference group: patients who were adherent to all 3 preventive therapies. Hazard ratios (HRs) are adjusted for patient characteristics shown in Online Table 2 and total
intensive care unit and inpatient days. ACEI/ARB¼ angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; CI¼ confidence interval; K-M¼ Kaplan-Meier.
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1550mortality tended to be stronger in men than women
(p value for sex*adherence group 0.031) and in
younger age groups than the oldest one (P value for
age group*adherence group ¼ 0.097).
DISCUSSION
In our cohort of older Medicare beneficiaries, 30%
were nonadherent to ACE inhibitors/ARBs, and
almost 25% were nonadherent to beta-blockers and
statins, respectively, at 6 months after discharge.
These nonadherence rates are comparable to those
reported recently among older post-AMI survivors in
the United States (5). Among those who received ACE
inhibitors/ARBs, beta-blockers, and statins within a
month after AMI hospitalization, all-cause mortality
rates among patients who were adherent to ACE in-
hibitors/ARBs and statins only did not differ from
rates among those who were adherent to all 3 thera-
pies. Nonadherence to ACE inhibitors/ARBs or statins
in any combination and nonadherence to all 3 thera-
pies in particular was associated with notably higher
mortality. These associations were broadly similar in
patient subgroups defined by sex, age, presence of
heart failure, diabetes, and dementia.
Our findings are intriguing for long-term medical
management of older patients after AMI. Clinical
guidelines recommend all 3 therapies, ACE inhibitors/
ARBs, statins, and beta-blockers, for long-term use as
secondary prevention after AMI; however, their ben-
efits were demonstrated in randomized controlledtrials for a single therapy rather than combinations
(16,17). Clinical uncertainties exist as to the clinical
impact of adherence to some therapies versus all 3 in
the long term. In clinical practice, this is a particularly
challenging issue for older adults with multiple
morbidities and polypharmacy. The high prevalence
of comorbidities and polypharmacy may markedly
increase the risk of adverse drug events and drug–
drug interactions, which is further complicated by
more prevalent cognitive impairment in older people.
Occurrence of adverse drug events accompanied with
the physical and cognitive burdens of taking many
medications may render long-term adherence to all 3
AMI preventive therapies unrealistic, though desired.
We found that, among patients who had all 3
therapies after AMI hospitalization, being adherent to
ACE inhibitors/ARBs and statins only was associated
with equal survival as being adherent to all 3 thera-
pies. Nonadherence to ACE inhibitors/ARBs or statins
in any combination in particular was associated with
notably higher mortality. Thus, our findings suggest
that long-term adherence to ACE inhibitors/ARBs and
statins may be more important than adherence to
beta-blockers after AMI. Prior, smaller studies from
the United States (1,21) and other countries (3,9,22)
also showed larger reductions in all-cause mortality
for adherence to statins and ACE inhibitors/ARBs
than adherence to beta-blockers. Accordingly, in a
large observational study (n ¼ >44,000), beta-
blockers were not associated with mortality benefit
in patients with prior MI or those without a history of
FIGURE 3 HRs (95% CIs) of All-Cause Mortality by Adherence to Various Combinations of Preventive Therapies in Subgroups Stratified
by Presence of Heart Failure, Diabetes, and Dementia, and Age and Sex
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Reference group: patients who were adherent to all 3 preventive therapies. HRs are adjusted for the patient characteristics shown in
Online Table 2 and total intensive care unit and inpatient days. Abbreviations as in Figure 2.
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1552AMI (23). Our observations support the argument that
in the current clinical practice, incremental survival
benefits associated with use of beta-blockers may be
smaller than benefits associated with use of the other
2 evidence-based preventive therapies (23–25).
Although the associations between adherence
groups and mortality were generally similar among
patients in subgroups as in the whole cohort, several
variations are notable. The increase in mortality risk
associated with being adherent to ACE inhibitors/
ARBs only was considerably smaller among patients
with heart failure than among patients without heart
failure. Among patients with heart failure, there was
no statistically significant difference in mortality risk
between patients who were adherent to ACE
inhibitors/ARBs only and those who were adherent to
all 3 therapies. The findings are in line with the
landmark clinical trials that have demonstrated ACE
inhibitors/ARBs as cornerstone therapy in reducing
mortality among patients with heart failure including
those after AMI (26,27). In our heart failure subgroup,
mortality in patients nonadherent to statins and
those adherent patients did not differ. This is also
consistent with 2 clinical trials that found no overall
CVD risk reduction in Class II to IV heart failure pa-
tients treated with statins (28,29). The pivotal trials
such as MERIT-HF (Metoprolol CR/XL Randomised
Intervention Trial in-Congestive Heart Failure),
COPERNICUS (Carvedilol Prospective Randomized
Cumulative Survival), and CIBIS-II (Cardiac Insuffi-
ciency Bisoprolol Study II), showed that beta-blockers
are associated with lower all-cause mortality in heart
failure (30–32). Our study suggests large relative
benefit of beta-blocker adherence in reducing mor-
tality in comparison to nonadherence to all 3 thera-
pies among patients with heart failure. However,
there was no benefit of beta-blocker adherence in
reducing mortality in comparison to patients with
heart failure and already adherent to ACE inhibitors/
ARBs. This finding was a surprise to us. One possible
explanation has to do with age. In the MERIT-HF,
COPERNICUS, and CIBIS-II trials, the mean age of
the patients was 61 to 64 years, whereas in our study,
the patients were 77 years of age on average. In line
with us, in the SENIORS (Study of Effects of Nebivolol
Intervention on Outcomes and Rehospitalization in
Seniors with Heart Failure) study in older heart fail-
ure patients (age >70 years), nebivolol, a beta-
blocker, failed to reduce mortality (33). Further
research on this is warranted.
By contrast, adherence to ACE inhibitors/ARBs and
statins conferred a greater benefit in patients with
diabetes than among patients without diabetes.
These findings suggest that it may be most importantto be adherent to ACE inhibitors/ARBs among pa-
tients with heart failure and to ACE inhibitors/ARBs
and statins among patients with diabetes post-AMI.
Meta-analyses of clinical trials have shown that ACE
inhibitors/ARBs and statins reduce all-cause mortal-
ity among patients with diabetes (34,35). Current U.S.
national guidelines recommend ACE inhibitors and
statins as first-line therapy for patients with diabetes,
hypertension, and CVD (36–38).
We found markedly higher mortality risk for being
adherent to beta-blockers only among patients with
diabetes or dementia than among patients without
these conditions. This suggests that being adherent to
beta-blockers in the long-term may not be as benefi-
cial for patients with diabetes or dementia as among
patients free of these conditions. Recently, a study
conducted among w16,000 U.S. nursing home resi-
dents found that among AMI survivors with moderate
or severe cognitive impairment, the use of beta-
blockers was associated with a 30% increased risk of
experiencing functional decline over a 3-month
period post-AMI (39). No such association was
observed among survivors without cognitive impair-
ment. Concerns have also been raised regarding the
negative effects of beta-blockers on glycemic control,
insulin sensitivity, masking of hypoglycemia, and
dyslipidemia. Meta-analyses of clinical trials have
shown that use of beta-blockers was associated with
higher risk of new-onset diabetes than non-diuretic
antihypertensive medications (40,41). The clinical
implications of our findings need to be investigated in
further studies.
STUDY LIMITATIONS. First, we restricted our study
population to the patients who filled prescriptions for
each of the 3 therapies shortly after hospital
discharge. This feature of our study most likely en-
hances comparability of adherence groups; however,
it precludes generalization of our results to situations
where decisions are made to stop or not initiate pre-
ventive therapies among patients who are not eligible
to all the 3 therapies at discharge. Second, due to our
reliance on prescription refill data, we could not
differentiate the tradeoff in adherence to multiple
therapies as physicians’ decision to discontinue
medication or patient’s/care taker’s decision not to
refill prescriptions. Third, although we adjusted our
outcome models for a comprehensive list of baseline
risk factors for potential adverse effects or intolerant
conditions for therapies and mortality, including
variables suggestive of pre-admission frailty, residual
confounding by unmeasured factors such as use of
aspirin may exist. However, the residual confounding
may be limited in the comparisons between patients
who were adherent to at least 1 therapy and those
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Nonadherence to statin and angiotensin inhibitor
therapy among survivors of myocardial infarction (MI) may
reduce survival, whereas adherence to beta-blockers may not be
beneficial to patients with dementia or diabetes.
TRANSLATIONAL OUTLOOK: More research is needed to
provide information on the risks and benefits of various combi-
nations of guideline-recommended post-MI preventive therapies
in patients with specific comorbidities, such as heart failure,
diabetes, or dementia.
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1553adherent to all 3 therapies. By contrast, the estimates
comparing patients who were adherent to none of the
3 therapies to those adherent to all therapies are
likely to be affected by significant unmeasured con-
founding. Finally, due to relatively small numbers of
patients in non-white subgroups of our study popu-
lation, we did not conduct race-specific analyses. This
important question should be addressed in future
studies.
CONCLUSIONS
Those patients who were adherent to ACE inhibitors/
ARBs and statins, but nonadherent to beta-blockers,
had a similar mortality risk as those adherent to all
3 therapies, suggesting the role of post-MI beta-
blockers in the statin and ACE/ARB era deserved
further investigation. Nonadherence to ACEI/ARB or
statins in any combination and nonadherence to all 3
therapies in particular was associated with higher
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